RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Atrium Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.61−0.06 (-0.78%)
Close on Oct 19, 2026
- Market cap
- $130.18M
- P/E (TTM)
- –
- Dividend yield
- –
Atrium Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Atrium Therapeutics | Industry median |
|---|---|---|
| Market Cap | $130.17M | $166.30M |
| Enterprise Value | -$133.73M | $88.19M |
| PB Ratio | 0.61 | 2.03 |
| P/TBV Ratio | 0.61 | 2.29 |
Balance sheet
| Measure | Atrium Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $263.90M | $61.43M |
| Net Cash (Debt) | $263.90M | $15.35M |
| Net Cash Per Share | $15.43 | $0.66 |
| Equity (Book Value) | $214.58M | $49.09M |
| Book Value Per Share | $12.54 | $1.37 |
| Tangible Book Value | $214.58M | $23.52M |
| Working Capital | $243.54M | $76.81M |
Financial position
| Measure | Atrium Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 8.73 | 3.34 |
| Quick Ratio | 8.38 | 2.44 |
Shares
| Measure | Atrium Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 17,105,600 | 58,127,000 |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 16,585,300 | 49,136,700 |
| Shares Held by Insiders | 3.04% | 11.6% |
| Shares Held by Institutions | 90.6% | 59.4% |
Scores
| Measure | Atrium Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 2.19 | -0.22 |
Calculated by StockData from Atrium Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.